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SUMMARY              
Title: Progesterone as therapy or prophylaxis in pregnancy  
Author: Ann Sofia Sundin 
Background and aims: fecundability of humans is quite low compared to the majority of 
other species and further impairment of fertility has been noticed in recent decades. An 
estimated twenty percent of pregnancies miscarry. Early and late pregnancy loss leaves 
great emotional stress and burdens both partners with a lot of unanswered questions. 
Preterm birth (PTB), defined as a delivery of a live born infant before 37 weeks or 259 
days of pregnancy complicates a bit over 12% of all US deliveries and it is one of main 
causes of neonatal morbidity and mortality. Therefore it is clear that there is a need for 
further research to discover a successful treatment to these conditions. Since 
progesterone is the essential pregnancy hormone, various randomized controlled studies 
have been made with the aim to bring clarity to wether or not the supplementation of 
progesterone really is effective in improving the pregnancy outcome when used as a 
treatment for threatened miscarriage and/or preterm delivery. The aim of this paper is to 
present a comprehensive review of literature on the effects of progesterone 
supplementation in pregnancy. With ambiguous results of research so far, a better 
understanding of progesterone’s role in pregnancy is being sought for. 
Methods: PubMed, Cochrane Library and Google scholar were primary sources for finding 
relevant material. Search was limited to English articles and terms included were: 
progesterone in pregnancy; recurrent miscarriage; recurrent pregnancy loss; preterm 
delivery; habitual abortions and therapy. The main criteria in the selection process was to 
find a good selection of published evidence-based research as well as avoiding outdated 
articles. 
Findings: There is still inconsistency of results regarding progesterone’s role as therapy 
or prophylaxis in pregnancy with results from two of the newest and largest studies 
contradicting each other. It is therefore still questionable whether or not progesterone 
should still be recommended as therapy or prophylaxis in pregnancy and which of the 
factors are of the greatest value when estimating the possible outcome of its use. Further 
research with larger groups is needed.  
Key words: progesterone; miscarriage; preterm delivery; habitual abortions. 
SAŽETAK 
Naslov: Terapijsko ili zaštitno djelovanje progesterona u trudnoći
Autor: Ann Sofia Sundin 
Pozadina i ciljevi: Dvadeset posto trudnoća završi pobačajem. Gubitak trudnoće ima 
negativne posljedice za emotivno stanje žene a također ostavlja brojna neodgovorena 
pitanja o njihovom fizičkom oporavku. U razvijenim zemljama prijevremeni porođaj 
komplicira oko 12% porođaja i definira se kao rođenje djeteta prije 37. tjedna ili 259 dana 
trudnoće. Prijevremeni porođaj predstavlja značajan rizik za neonatalni morbiditet i 
mortalitet. Još uvijek ne postoji jasno definiran terapijski pristup za liječenje ili sprječavanje 
prijevremenog porođaja. Obzirom da je progesteron esencijalni hormon trudnoće, brojna 
istraživanja i meta-analize su učinjene kako bi se definiralo je li nadomjesno liječenje ovim 
hormonom zbilja učinkovito u poboljšanju ishoda prijetećeg pobačaja i/ili prijevremenog 
porođaja. Obzirom na oprečne rezultate dosadašnjih istraživanja traži se bolje 
razumijevanje uloge progesterona u trudnoći. Cilj ovog rada je sveobuhvatni pregled 
literature o učincima progesterona u trudnoći i učincima nadomjesne progesteronske 
terapije.  
Metode: Analizirani članci nađeni su pretraživanjem baza PubMed, Cochrane Library i 
Google scholar. Svi članci koji su uzeti u obzir bili su na engleskom jeziku. Pojmovi koji su 
korišteni kod pretraživanja su: progesteron u trudnoći, rani gubitak trudnoće, ponavljajući 
spontani pobačaj, prijevremeni porođaj, habitualni pobačaj i terapija. Glavni kriteriji pri 
odabiru radova koji su uključeni u analizu bilo je pronalaženje članaka temeljenih na 
znanstvenim istraživanjima i dokazima, kao i izbjegavanje zastarjelih članaka. 
Zaključak: Još uvijek postoje nedosljednosti u pogledu uloge progesterona kao terapije ili 
profilakse u trudnoći. Rezultati najnovijih i najvećih studija su proturječni. Stoga, još uvijek 
nije jasno definirana terapijska ili profilaktična uloga progesterona u trudnoći, te koji 
čimbenici imaju najveću vrijednost kod procjene mogućeg ishoda njegove uporabe. 
Potrebna su daljnja istraživanja s većim skupinama. 
Ključne riječi: progesteron; spontani pobačaj; habitualni pobačaji, prijevremeni porođaj 
1. INTRODUCTION  
Progesterone as a key hormone in human reproduction is synthesized and secreted by 
ovaries and adrenal glands. It has an important role in both follicular and secretory phases 
of the menstrual cycle and is crucial for embryo implantation and development of a 
successful pregnancy. The effects of progesterone are mediated by nuclear progesterone 
receptors, PR-A and PR-B. These receptors are expressed in the ovary, the uterine 
endometrium and myometrium, preovulatory granulosa cells, other reproductive tissues, 
endocrine organs such as the hypothalamus-pituitary complex as well as other tissues 
where its’ role is less clear.1 
During the follicular phase progesterone is mainly produced in the pathway of estrogen 
production. A high concentration of estrogen during a sustained period of time provokes 
ovulation as well as an increase in progesterone production as a response to a pituitary LH 
surge. After ovulation the corpus luteum is formed from theca and granulosa cells together 
with blood resorbed from the surrounding ruptured vessels caused by the follicle rupture.1 
The corpus luteum is responsible for progesterone secretion and is reliant on pulsations of 
the LH. Progesterone inhibits new folliculogenesis as well as diminishes the frequency and 
amplitude of GnRH and LH peaks. Concentration of progesterone peaks in the middle of 
the luteal phase and helps the endometrium to prepare for implantation as well as nourish 
the fertilized ovum by inducing endometrial protein secretion. By the end of the menstrual 
cycle, the LH sensitivity is decreased and is not sufficient to maintain the corpus luteum. 
This gives an explanation of why the corpus luteum regresses after 12-16 days if 
fertilization fails to occur, and as a consequence of the demised corpus luteum, 
progesterone levels drop. Since estrogen and progesterone are main influencers of the 
proliferative and secretory changes of the uterine endometrium, the decreased levels 
resulting from the demised corpus luteum will also cause changes great enough to cause 
interruption of endometrial blood supply and a subsequent shredding of its superficial, 
proliferative layer, also called the decidua functionalis.2 This marks the end to the luteal 
phase as well as the beginning of a new menstrual cycle by the onset of menstruation.3 
When fertilization occurs, the blastocyst implants into the uterine endometrium 
approximately nine days post ovulation. Human chorionic gonadotropin (hCG) produced 
by the embryo disrupts the menstrual cycle by stimulating the corpus luteum to continue 
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the production of estrogen and progesterone. The surge in estrogen and progesterone 
prevents the endometrial shedding that would otherwise occur. The corpus luteum 
production of progesterone is critical for the maintenance of pregnancy in the first trimester 
until the placenta takes over this function at approximately 7 to 8 weeks of gestation. Even 
though placentation is initiated shortly after fertilization, the placenta is not mature enough 
to produce sufficient levels of progesterone on its own during these early weeks of 
gestation. The LH action is mimicked by the hCG which acts on the corpus luteum and 
ensures adequate progesterone levels in order to avoid pregnancy loss. 
Progesterone is not only contributing to the thickening of the endometrium as preparation 
for implantation of the embryo but also supports pregnancy maintenance by providing 
endometrial secretory transformation, ensures uterine quiescence, and inhibits 
contractions of the uterine myometrium. These mechanisms of action of progesterone are 
indeed complex. Progesterone endometrial effects are dependent on estrogen that causes 
an increase in endometrial progesterone receptors during the proliferative phase of the 
menstrual cycle. By various actions, progesterone opposes the effect of estrogen causing 
diverse stromal and epithelial effects, leading to improved endometrial receptivity for 
possible implantation of  an embryo. Regardless of the complex mechanism, insufficient 
progesterone action causes alteration in the hormonal balance between progesterone and 
estrogen, effecting critical steps in the acquisition of an ideal uterine receptivity for 
embryonal implantation.4  
It is indisputable that proinflammatory cytokines play a critical part in delivery, regardless of 
if there is an associated infection present or not and whether or not the delivery is at term 
or preterm. Proinflammatory cytokines cause activation of the myometrium and 
prostaglandin synthesis.5 An increased prostaglandin synthesis causes cervical ripening 
and stimulation of uterine contractions which triggers the initiation of labour by increasing 
myometrial gap junctional communication as well as the receptors for oxytocin and 
arginine vasopressin.5,6 Progesterone is proposed to ensure uterine quiescence by 
inhibiting the prostaglandin synthesis.7 The presence of progesterone also contributes to 
the prevention of ovulation during pregnancy, reassures the growth of mammary glands 
essential for upcoming breastfeeding and have various actions on the immunomodulatory 
and anti-inflammatory elements essential for a successful pregnancy. It is therefore 
essential that progesterone levels remain elevated throughout pregnancy in order to 
ensure pregnancy maintenance. Indeed, removal of the source of progesterone by 
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removing the corpus luteum (luteectomy), as well as administration of progesterone 
receptor antagonists such as mifepristone (RU-486) readily induce abortions.8,9,10 This 
hypothesis was further improved when exogenous progesterone administration was shown 
to prevent abortion after luteectomy. It is therefore understandable that any change in 
production, metabolism and concentration of progesterone can have various impacts to 
pregnancy maintenance, i.e. increase a risk of early pregnancy loss as well as 
compromise the later pregnancy physiology.  
Not only are fertilization and implantation extremely complicated fields in medicine, there is 
also a variety of possible pregnancy complications. Preterm birth, defined as a delivery of 
a live born infant before 37 weeks or 259 days of gestation is currently one of the most 
common pregnancy related complication in developed countries, complicating one in eight 
deliveries in the US and accounts for a considerably increased risk of neonatal morbidity 
and mortality.11 
As mentioned above, progesterone has an essential role in early pregnancy.12 
Progesterone stimulates vascularization in the growing endometrium that aids the 
development of fetal circulation and provides myometrial quieting by opposing actions of 
myometrial contraction. The importance of progesterone in myometrial quieting throughout 
the pregnancy is proven by the parturition induction as the outcome of anti-progestin 
administration.13,14 Administration of progesterone receptor antagonists such as 
mifepristone (RU-486) affect endometrial function and implantation and causes abortion in 
over 95% of early pregnancies.  
By the variety of actions mentioned above, progesterone is able to impede cervical 
ripening and maintain uterine quiescence by suppressing chemokine synthesis, thereby 
hindering parturition.15 
In 2011 the US Food and Drugs Administration (FDA) approved a medication for preterm 
birth prevention in the form of progesterone.11 Progesterone’s roles as therapy or 
prophylaxis in pregnancy have been presumed many. Different randomized trials have 
been designed to establish its reliability in in vitro fertilization (IVF) outcome, for prevention 
of preterm birth, including women with a short cervix, as well as in the management of 
recurrent pregnancy loss (RPL). 
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Most authorities recommend progesterone supplementation in assisted reproductive 
technology (ART) in order to increase the success rate.12 
However, progesterone’s efficacy in the prevention of preterm birth has not been as 
successful as it was first anticipated. Despite numerous published studies about it’s role in 
pregnancy, there is still no consensus about it’s efficacy in the prevention of spontaneous 
preterm birth. Some studies suggest a reduced risk, while others do not. A significant 
number of researches has been done in recent years with the aim to bring clarity to these 
questions. However, there are still notable gaps to be filled. The latest published meta-
analysis regarding progesterone’s role in preventing preterm birth is a Reuters Health 
meta-analysis, published in December 2017. The data from 974 women provides us with 
convincing evidence that vaginal progesterone does reduce the risk of preterm birth, as 
well as perinatal morbidity and mortality in singleton gestations where the woman had a 
short cervical length, defined as 25 mm or less.17 This contradicts the result of the 
OPPTIMUM study from May 2016, a slightly larger study with data from 1228 women and 
the largest randomized trial when it comes to identifying the efficacy of vaginal 
progesterone in preventing preterm birth in high risk women. The OPPTIMUM study 
strongly suggests that the efficacy of progesterone is non-existent or weak in this field of 
application.18 
The aim of this review is to gain a better understanding of why previous data show such a 
diversity in results when it comes to progesterone therapy and prophylaxis in pregnancy. 
What differed in the approach and patient selection that made the results so ambiguous?  
Progesterone supplementation is indeed suggested to be efficient in the PTB prevention in 
some women at high risk, however new research has given us a good reason not to 
consider progesterone as ‘’a cure-all’’ but to raise questions about which patients might 
benefit from the treatment. This thesis will review the controversy related to progesterone 
supplementation in habitual abortions, threatened miscarriage and PTB in singleton versus 
multiple gestation pregnancies, as well as the difference in progesterone preparation and 
dosing. The aim is to answer if there is enough systematic reviews on this topic to assure 
whether or not progesterone should continue to be used in these circumstances or 
considered obsolete. 
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2. TYPES OF PROGESTERONE 
Progesterone is a natural progestogen, a sex steroid secreted by the corpus luteum and 
subsequently the placenta, as well as the cortex of the adrenal gland.19,20 Most commonly 
used preparations of progesterone in pregnant women in clinical practice today are natural 
micronized progesterone, 17-alpha hydroxyprogesterone caproate (17-OHPC) and 
dydrogesterone. 
2.1 Natural micronized progesterone 
The bioidentical micronized progesterone is as the name suggests a natural form of 
progesterone and is composed of fine dispersed particles made in the lab in order to 
provide the best possible uptake in the body. This type of progesterone is self-
administered and the route of administration is either oral or vaginal. Natural micronized 
progesterone is widely used in obstetrics and gynecology by showing efficient results with 
minimum side effects.21 Side effects most commonly seen in women taking the natural 
micronized progesterone include depression, breast tenderness, dizziness, nausea and 
vomiting, as well as bloating. These side effects can be minimized by taking the 
supplementation before bedtime. According to a study by Marinov et al., natural 
micronized progesterone shows equal effectiveness when administered through the oral or 
the vaginal route when prescribed for threatened miscarriage during the first trimester or 
as a prophylaxis for preterm delivery in women with either a short cervix or a previous 
history of preterm delivery.21,22 This result contradicts many other studies, where the 
majority are showing a significantly higher serum progesterone concentration and a higher 
number of term deliveries when micronized progesterone is administered through the 
vaginal route.23,24,108,109 The oral form provides greater and durable patient compliance by 
offering continuous effectiveness by a more or less effortless route or administration. 
However, the oral form is susceptible to a first-pass hepatic effect and thereby causes a 
decrease in potency as well as unfavorable side effects.23 The vaginal route, usually in the 
form of a gel or suppository is not exposed to the first-pass hepatic effect and has less 
side effects than the oral route. It achieves greater uterine concentrations by it’s instant 
absorption from the vagina to the endometrium where is causes secretory changes.23,24 
Even though the vaginal route might not be as convenient for the patient as the oral route, 
it is still self-administrable by the patient and the benefits of the vaginal route have made 
this form the main route of administration. For preterm delivery prevention, natural 
micronized progesterone together with 17-OHPC are the forms of progesterone that are 
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most commonly used.23 In general, the therapy tends to be well tolerated with most 
reported side effects being mild and transient. 
2.2 17-alpha hydroxyprogesterone caproate (17-OHPC)  
The counterpart of the natural progesterone is a synthetic form of progestogen 17-alpha 
hydroxyprogesterone caproate.25 It should not be confused with the endogenous derivative 
of progesterone, 17-alpha hydroxyprogesterone. Since it is ineffective by the oral route, 
the main route of 17-OHPC administration is intramuscular.23 When administered by the 
intramuscular route it has been shown to reduce the incidence of preterm delivery 
extensively.26 It also decreased a risk of pregnancy complications in women with a 
previous preterm delivery when administered in a dose of 250 mg as weekly injections.26,27 
A trial by Meis et al. showed that weekly intramuscular injections of 17-OHPC significantly 
decreased a risk of a preterm delivery before week 37 of gestation in women with a 
previous spontaneous preterm delivery, and there was also a lower incidence of neonatal 
complications such as a necrotizing enterocolitis and supplemental oxygen need.28 Due to 
promising results, this trial provided clinical indications for 17-OHPC use in preterm birth 
prevention. Since 17-OHPC is administered through the IM route, pain and swelling at the 
injection site is one of the most commonly reported side effects. Other side effects include 
hives, pruritus, nausea and vomiting. 
2.3 Dydrogesterone 
Dydrogesterone is a synthetic derivative of progesterone used in various gynecological 
conditions such as infertility and threatened or habitual abortions due to its good oral 
bioavailability, tolerability and potency as well as safety.29 Dydrogesterone is readily 
absorbed in the GI tract with a bioavailability of 28% even at low doses. Dydrogesterone’s 
oral form gives a high compliance and just like the micronized progesterone, it has the 
benefit of acting directly on the uterus, exhibiting anti-estrogen activity able to cause 
secretory changes of the endometrium.30 Despite its structural and pharmacological 
similarity to endogenous progesterone, dydrogesterone is efficient in much lower oral 
doses and does not possess as high of a risk of unsatisfactory hormonal side effects such 
as menstrual irregularities like spotting, breast tenderness, weight gain, edema, acne and 
libido changes and is therefore beneficial over most endogenous progesterones as well as 
the majority of other synthetic progestogens. The most frequent side effects from 
dydrogesterone is bloating, vertigo, nausea, and vomiting. Prescribing information also 
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mention infrequent side effects including liver function alternations and therefore caution 
has to be taken in patients with acute or chronic liver diseases with abnormal liver function 
tests.  
A 2016 systematic literature review analyzed 9 randomized trials totally including 913 
pregnant women and showed a lowering of threatened abortions in the women receiving 
oral dydrogesterone or vaginal progesterone in comparison to the placebo group.31 
However, there was no clear difference between these two administration routes of 
progesterone.31 Another review published in 2012 analyzed data from five randomized 
trials with 660 pregnant women with threatened miscarriage, 335 of them receiving 
dydrogesterone.29 The dose somewhat differed from one trial to another with a standard 
dose of 10 mg BID.29 Result showed a 47 percent decrease in the risk for miscarriage as 
well as minimal side effects. 
Other small sample size studies also showed promising results of dydrogesterone 
treatment over placebo in maintaining pregnancy until 20 weeks of gestation.32-34 These 
studies did indeed show a lower incidence in spontaneous miscarriage in women receiving 
dydrogesterone in comparison to the group not receiving therapy and did not show any 
convincing discrepancy in congenital malformations. However, due to the small sample 
size and poor study quality larger sample size studies should be more trustworthy. 
Dydrogesterone indeed appears to be beneficial in miscarriage prevention in threatened 
abortions and does not show an increased risk for any congenital abnormalities. 
3. ROUTE OF PROGESTERONE ADMINISTRATION 
Three main routes of progesterone administration are oral, vaginal and intramuscular (IM) 
and are all effecting the pharmacokinetics. The initial administration of progesterone back 
in 1997 was by the vaginal route in a form of a gel, followed by an oral capsule in 1998, an 
intramuscular injection in 2001, and a vaginal suppository in 2007.35,36,37 
3.1 Oral progesterone 
Even though the oral route of progesterone administration is likely a route with the highest 
compliance, it is seldom the preferred route. The absorption and clearance of orally 
administered progesterone has been proven to be less beneficial compared to other forms. 
16 This is due to the high first-pass metabolism of progesterone by the liver, leading to 
nonuniform blood levels, less potency, as well as an increased risk of side effects. Due to 
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the low bioavailability (only 10 percent of the IM type) and the major absorption differences 
depending on food intake, the oral route is seldom preferred as the main route of 
progesterone delivery. However, the use of synthetic progestogens over natural 
progesterone is less effected by the liver metabolism and therefore has a higher 
bioavailability.38,39,40 Due to the poor GI absorption of oral progesterone, the oral 
preparations should not be prescribed in assisted reproductive technology due to the lower 
success rate in comparison to the other formulations.16 
Since the half-life of micronized progesterone taken by the oral route is approximately 17 
hours, with peaking concentrations seen after 2-4 hours, the typical dose interval is two to 
three times a day.17,41 The serum concentration will remain elevated for approximately 12 
hours but the reestablishment of the baseline level value will occur first after 24 hours.17 
Neurosteroids are metabolites of progesterone potentiating GABAA receptors and are the 
cause of unwanted sedative side effects of progesterone. Other side effects include 
everything from nonspecific flu-like symptoms, breast tenderness, dysmenorrhea, irregular 
bleedings, to systemic and sedative side effects such as fatigue, nausea and vomiting.42 
Since the oral dose of progesterone tends to be higher compared to the IM and vaginal 
route, side-effects of oral progesterone are more frequent. 
3.2 Intramuscular progesterone 
The IM route shows good absorption with high blood concentration peaking 8 hours after a 
10 mg injection as well as a possible progesterone depot with accumulation in adipose 
tissue.43 In that case, IM progesterone would give a more constant concentration in 
comparison to the other routes of administration. Serum progesterone reaches luteal 
phase levels when doubling the initial dose of 10 mg IM progesterone and reaches mid-
pregnancy levels if the dose is increased tenfold.44 This causes exalted levels of serum 
progesterone for a minimum of 48 hours. Although fairly efficient, intramuscular 
administration is not too convenient and reduces the likelihood of compliance since it is an 
uncomfortable way of administration. It possesses a risk of tissue irritation such as 
discomfort, pain, inflammation and bruising.45 Even though oral progesterone has 
considerably more sedative side-effects, IM progesterone is capable of causing similar 
side-effects if administered in adequately high dose, thus demonstrating that the liver 
metabolism of progesterone into neurosteroids like allopregnanolone is not necessarily 
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crucial for these sedative effects to ensue. Since IM progesterone has the capacity to 
reach high serum levels, it it capable to coerce anterior pituitary secretion of 
gonadotropins, showing antigonadotropic efficacy and thereby decreased production of 
sex hormones.16 IM preparations are connected with greater serum levels while greater 
uterine concentrations are seen with vaginal preparations.16 Both vaginal and IM 
progesterone preparations are the formulations with documented beneficial effects on 
assisted reproductive technology outcome.16 
3.3 Vaginal progesterone  
The benefit of vaginal progesterone is that this route of administration bypasses the first-
pass metabolism by the liver and intestines that the oral route is exposed to, as well as 
avoiding the uncomfortable and troublesome administration that the IM route requires.24 
The relatively uncomplicated way of application together with the absence of systemic side 
effects and the favorable pharmacokinetic characteristics has made the vaginal route the 
preferred route of progesterone delivery.46 Since the vaginal route is less of a burden for 
the patient in comparison to the IM route, it increases the likelihood of compliance. Also, 
the bioavailability is greater, showing increased uterine concentrations suggestive of 
sufficient delivery of progesterone from the vagina to the uterine endometrium. This is 
contributing to uterine quiescence by regulating the expression of the uterine progesterone 
receptor genes responsible for myometrial contractility regulation.11,24 Research showed 
that the vagina could function as a progesterone reservoir but is also capable of causing 
unwanted side-effects such as discharge and irritability.43 Peak plasma concentrations are 
reached 3-8 hours post-admission of vaginal progesterone. The usual daily dose of vaginal 
progesterone is 300-600 mg, divided in 2-3 dosages. The vaginal route requires a higher 
dose and the plasma concentration drops faster in comparison to the IM route.43 
Growing trial evidences propose that the vaginal route of progesterone administration 
could be the superior route due to its hypothesized uterine first-pass effect, providing a 
superior uterine bioavailability in comparison to the oral and IM route. Nonetheless, 
continuous randomized trials are needed to properly confirm the supremacy of the vaginal 
administration route in comparison to the other routes as well as the ideal dosing of the 
formulations. 
In general, the vaginal or IM form is superior to the oral form as the route of choice. By 
avoiding the oral dose, it is possible to bypass progesterone’s exposure to the metabolic 
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first-pass effect by the liver as well as the large doses needed in the oral form, thereby 
being more efficient.38-40 This further reduces undesirable side effects of progesterone like 
drowsiness and irritability.42 
4. COMBINING INTERACTIONS 
Combining interactions are seen in circumstances where progesterone therapy is used in 
combination with another intervention. Adjunctive use of progesterone and cerclage can be 
seen in cases with cervical insufficiency. A cerclage is a prophylactic procedure where 
sutures are put around and into the cervix in order to support the cervix during pregnancy 
and prevent the risk of ascending infections and decrease the risk of pregnancy loss or 
premature delivery. Progesterone on the other hand is contributing to uterine quiescence 
and the combining interaction of progesterone and cerclage was therefore anticipated to 
bring greater effectiveness in reducing the risk of miscarriage and PTB.  
Ultrasound measurement of a cervical length of 20 mm or less has been proposed for 
induction of prophylactic progesterone treatment with or without cerclage.47 Collected data 
show an equal efficiency of cerclage and vaginal or IM progesterone in women with a 
sonographic short cervical length and a history of PTB during the mid trimester.48,49,50 
However, no randomized controlled trial has directly compared progestogen administration 
to cervical cerclage for the prevention of PTB in women with a sonographic short cervix in 
the midtrimester, singleton gestation, and previous PTB.48,51 The result of a 2012 study 
showed equal effectiveness of vaginal progesterone and cerclage in lowering the risk of 
preterm delivery and negative perinatal outcomes before week 32 of gestation.48 However, 
when used as separate interactions, studies have shown greater efficacy of cervical 
cerclage than vaginal progesterone.52 The results of a very recent prospective cohort study 
by Sinkey et al. did not show any benefit in combining vaginal progesterone with cervical 
cerclage over cerclage alone in decreasing PTB.49  
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5. SINGLETON VS MULTIPLE-GESTATION 
PREGNANCIES 
5.1 Singleton gestations  
A previous spontaneous preterm birth possess a greater risk of another PTB in 
consecutive gestations.28 Vaginal progesterone in women with a singleton gestation and a 
sonographic short cervix is shown to prevent preterm delivery.53,54 Even though some 
studies are lacking convincing evidence that IM injections with 17-OHPC would reduce the 
risk of PTB, numerous trials still suggest that it 17-OHPC may reduce the risk of PTB.55  
A double-blinded trial by Meis et al included women between week 16 to 20 of gestation 
until week 36 of gestation or the onset of a spontaneous preterm delivery.28 One group 
received weekly IM injections of 250 mg 17-OHPC and the other group received a 
placebo. Results of this study showed a 30 percent decrease of recurrent PTB in singleton 
gestations as well as a reduced risk of neonatal complications such as IVH and NEC when 
given 17-OHPC. The risk reduction was the greatest in pregnancies less than 37 weeks of 
gestation, followed by <35 weeks and <32 weeks of gestation compared to the placebo 
group. Due to promising results of this singleton gestation study, further studies were 
performed in order to estimate wether or not 17-OHPC therapy could also be useful in 
multiple gestations.56-62 Another randomized trial by Saghafi et al also evaluating the effect 
of weekly 17-OHPC injections was likewise correlating with a decreased risk of 
subsequent PTB in women with a previous PTB as well as an enhancement in birth 
weight.27  
Da Fonseca et al. as well as O’Brien et al. both evaluated the efficiency of micronized 
vaginal progesterone as PTB prevention in singleton gestations of women at risk of a PTB.
63,64 It is important to highlight that these two studies included only women with a history of 
previous spontaneous PTB’s and not by any diagnostic tools like a transvaginal 
measurement of the cervical length. Even though the trials had great similarities, the 
results contradict each other. The Da Fonseca trial did not only include women with a 
history of prior PTB but also included women with malformations of the uterus and those 
already receiving a cerclage.63 However, these included only a fraction of the trial group 
and should not be able to explain the great difference between the results from the two 
trials. This trial showed a reduction of PTB by reducing myometrial contractility and the 
amount of PTB in women at risk when receiving a daily dose of 100 mg of micronized 
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progesterone suppositories. The O’Brien trial from 2007 on the other hand did not include 
women with uterine malformations or cerclage and did not show any benefits of 90 mg 
micronized vaginal progesterone daily in reducing the rate of subsequent PTB’s prior to 
week 32 of gestation in women with a previous PTB.64 The O’Brien trial is larger than the 
Da Fonseca trial with 659 patients versus 149 patients.63,64 Since the trials were so similar 
in all other aspects; type of progesterone used, the route of application and the patients 
participating in the trials, it is difficult to anticipate what caused the ambiguous results.  
When evaluating the effect of oral micronized progesterone on the rate of PTB, a 
randomized trial by Rai et al. in 2009 indeed showed a reduction in subsequent PTB less 
than week 37 of gestation in women receiving a two times daily dose of 100 mg oral 
progesterone.65 Opposite results were however shown by Glover et al. who were unable to 
show any benefits of 400 mg oral micronized progesterone daily in comparison to placebo 
in reducing the rate of PTB.66 However, these trials 2have a greater variability in dosing as 
well as a smaller test group. It is therefore uncertain how reliable the contraindicating 
results are.  
5.2 Multiple gestations  
Just as in singleton gestations, multiple gestations are at risk of preterm delivery in women 
with a short cervix. However, a shorter cervical length is tolerated in a singleton gestation 
versus a multiple gestation in the same week of gestation. A cervical length of less than 15 
mm carry a 50 percent risk of a preterm delivery before week 32 of gestation in a singleton 
gestation.67 This can be compared to the equally high risk with a cervical length of less 
than 25 mm in a twin gestation.68 So the higher the number of gestations, the less 
tolerated is a short cervical length. A systematic review and meta-analysis published in 
2010 showed convincing results that sonographic cervical length measurement in weeks 
20 to 24 of gestation is a strong risk factor for spontaneous PTB in multiple gestations.69 
Conde-Agudelo et al gave the strongest evidence to date that transvaginal sonographic 
measurement of cervical length at 20-24 weeks of gestation is a good predictor of 
spontaneous preterm birth in asymptomatic women with twin pregnancies, stating that a 
cervical length ≤20 mm predicts spontaneous PTB at <32 and <34 weeks of gestation, 
whereas a cervical length ≤25 mm predicts PTB at <28 weeks of gestation.69 
After a publication by the National Institute of Child Health and Human Development-
Maternal Fetal Medicine Unit in 2003 showed a 30 percent decrease of recurrent PTB in 
 12
singleton gestations, weekly 250 mg 17-OHPC IM injections have also been encouraged 
for PTB prevention in women with short cervical length in multiple gestations as well as for 
nulliparous women.28 Different trials have been made in order to determine whether or not 
17-OHPC is efficient in preventing preterm delivery in multiple pregnancies.56-62 The 
hypothesis that a higher dose of progesterone is necessary to prevent preterm delivery in 
multiple gestations have failed to be proven correct.15 Regardless of the dose (90-200 mg) 
of progesterone administered and wether or not the trials have been made on twin or 
triplet pregnancies, the trials have failed to show any benefits or progesterone 
administration in preventing PTB in multiple pregnancies. Consequently there is no data 
proving that progesterone therapy would reduce the risk of preterm delivery in multiple 
gestations. 17-OHPC have failed to show any benefit in these circumstances.56-57 
Invasive procedures such as a rescue cerclage have also failed to show a significant 
reduction in PTB in women with multiple gestations and a short cervix and rather show an 
increased rate of detrimental outcomes.70,71 The difference in PTB between cerclage and 
no cerclage in twin pregnancies with a short cervical length is just marginal and actually 
shows an average of 0.4 weeks increase in gestational age at delivery in favor of no 
cerclage (P=.77) versus cerclage. However, there is a slight favor for cerclage over no 
cerclage seen in triplet pregnancies (P=.21).71 
From all the trials performed so far, it can be concluded that neither 17-OHPC or cerclage 
is prolonging pregnancy significantly enough to be recommended as a treatment in 
multiple gestations. The cervix shortens earlier in multiple versus singleton gestations and 
new research is trying to find the answer to wether or not cervical length shortening in 
multiple gestations can have an inflammatory element sensible to 17-OHPC.72,73 
Regardless of the reason why cerclage as well as progesterone therapy has failed to 
prove efficacy in multiple gestations, further trials are highly recommended in order to 
estimate which effective treatments could be offered to women with multiple gestations 
diagnosed with a sonographic short cervical length in order to prevent PTB. 
Progesterone prophylaxis is initiated the earliest in week 18 and latest in week 32 of 
gestation and is usually only given in singleton gestations due to the failing of showing 
benefits in multiple gestations. Usually a daily dose of 90-200 mg of vaginal progesterone 
is used until spontaneous rupture of the membranes or when reaching week 34 of 
gestation. 
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6. POSSIBLE INDICATIONS FOR PROGESTERONE 
SUPPLEMENTATION 
6.1 Short cervical length 
The cervical length is measured through a transvaginal ultrasound examination. The mean 
cervical length in a non-pregnant woman is between 40 and 50 mm. During pregnancy, the 
cervix shortens to an average length of 35 mm during week 24 of pregnancy.74 The 
definition of a short cervix is a cervical length of 25 mm or less during week 18-32 in 
pregnancy.47 These women possess a greater risk of having a preterm delivery. In the 
case of a cervical length of 20 mm or less, prophylactic progesterone treatment is 
recommended with or without other options like cerclage.47 There are different mechanism 
in which progesterone is believed to affect cervical ripening. Progesterone antagonist 
administration promote cervical ripening and the administration of mifepristone, a selective 
progesterone receptor modulator induced cervical ripening when tested on guinea pigs.75 
There is an increased cervical response to progesterone antagonists with progressive 
gestational age but this is not necessarily followed by alterations in the activity of the 
myometrium, suggesting that the cervix is the dominant location of progesterone action 
and not necessarily the myometrium as previously emphasized.76 The exact mechanism 
by which progesterone action blockage induces these cervical changes leading to cervical 
ripening is complex but is believed to be influenced by inflammatory processes like 
infiltration of leukocytes, chemokine and prostaglandin production as well as nuclear 
factor-kappa B which arbitrate the effect of interleukin-1B and tumor necrosis factor-α.77 
Since NF-KB is able to counter the effect of progesterone, it has a key role in providing 
cervical ripening.77,78 Since progesterone antagonists are proven to induce cervical 
ripening, it is understandable why progesterone became a promising pharmaceutical 
therapy in possible preterm birth prevention in women with a short cervical length. 
The OPPTIMUM study publication in 2016 included a total of 1228 women, with 618 
women receiving 200 mg vaginal progesterone prophylaxis.18 Even though the findings did 
not show any teratogenic or other harmful effects on outcomes during the first two 
postnatal years of children, it did not show any benefits and neither any reduction in the 
preterm delivery risk.18 It is therefore understandable that the OPPTIMUM publication lead 
to increased questioning wether or not progesterone is as efficient as previously stated 
when it comes to PTB prevention.17 
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However, various studies still show that progesterone prophylaxis is useful in prolonging 
pregnancy in women at increased risk of premature delivery, as well as results that 
progesterone does not possess any risk for the fetus, and improve the neonatal outcome. 
Romero R et al study included 775 women and 827 newborns and showed a significant 
decrease in PTB risk as well as perinatal complications in asymptomatic women with a 
short cervical length when administered vaginal progesterone.79 Women with a short 
cervix of 10-20 mm proven by sonography before week 24 of a singleton gestation given 
90 mg prophylactic vaginal progesterone showed a 45% reduction in preterm delivery 
before week 33 of gestation according to a 2011 published research involving 458 
asymptomatic women at risk of preterm delivery.53 
Also a new study from 2017 contradicts the results of the OPPTIMUM study.17 The study 
collected data from 974 women with singleton gestations and a cervical length of 25 mm or 
less during the mid-trimester, all receiving vaginal progesterone prophylaxis.17 The 
outcome opposed the results from the OPPTIMUM study by showing a convincing 
decrease in preterm delivery risk in women receiving progesterone prophylaxis over 
placebo as well as a reduction in RDS, neonatal morbidity and mortality and lower NICU 
admissions.17  
6.2 Threatened miscarriage 
Approximately 20% of all pregnancies miscarry, the majority prior to week 12 of gestation. 
A miscarriage before gestation week 13 is most commonly due genetic factors such as 
aneuploidy: an abnormal chromosome number, the most common being trisomy 16.80 The 
risk for aneuploidy is the highest at both extremes of maternal age. Somewhat 50% of 
miscarriages prior to week 13 are believed to be due to chromosomal abnormalities. 
Other factors contributing to the risk of miscarriage are infections throughout pregnancy. 
These could be both viral or bacterial, abdominal trauma, maternal age > 35 years, obesity 
and unregulated diabetes mellitus. Definition of a threatened miscarriage is presentation of 
signs and symptoms suggestive of a possible miscarriage when the pregnancy is less than 
20 weeks of gestation or a fetal weight is less than 500 grams.81 The most common single 
complaint in threatened abortion is early pregnancy bleeding. Vaginal bleeding, abdominal 
cramps with or without vaginal bleeding, together with a closed cervix are all signs and 
symptoms of a threatened miscarriage and must be taken seriously. In order to be labeled 
a threatened miscarriage, the fetus must still be viable within the uterus.82 Unfortunately, 
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pregnancy loss is unavoidable once cervical dilatation starts.80 Sonography is a useful tool 
in the diagnosis and management of threatened miscarriage since it is able to tell us 
wether the pregnancy is viable or non-viable, molar, or an unavoidable abortion.80,83  
Since progesterone has an essential role in both pregnancy establishment and 
maintenance, insufficient levels of this hormone have historically been associated with 
threatened miscarriage and vaginal bleeding. The hypothesis is therefore that it is the 
insufficient level of progesterone that is inevitably leading to miscarriage rather than 
progesterone lack as a secondary effect of an already failing pregnancy.84  
A publication from Everett et al back in 1987 showed that progesterone was prescribed as 
a treatment of threatened miscarriage in 13-40% of women.83,85 However there is limited 
newly published data about the frequency of progesterone administration in women with 
threatened miscarriage in recent years. Various meta-analyses had been made with the 
aim to bring clarity to whether or not progesterone really is effective in improving the 
pregnancy outcome when used as a treatment for threatened miscarriage. 
Different studies have been made to find an answer to whether a threatened miscarriage is 
associated with an increased risk of further pregnancy and perinatal complications. There 
is ambiguous data regarding the exact cause of a threatened miscarriage. Older studies 
found normal development despite threatened abortions, while a high number of recent 
research showed increased pregnancy and perinatal complications such as PTB and a low 
birth rate in these pregnancies which should be considered as high risk pregnancies.86-90  
A 2014 study by Ahmed et al. showed a link between threatened miscarriage and later 
pregnancy complications. Early gestational bleeding possesses a woman to an increased 
risk of a complete abortion, preterm birth, and a low birth weight of a baby. Hypertension 
and/or preeclampsia in pregnancy, placenta praevia, intrauterine growth restriction, 
premature rupture of membranes and cesarian section are slightly more common in these 
circumstances, leading to a higher rate of admissions to neonatal ICU.90 
A study by Omar et al. came to the conclusion that the risk of pregnancy loss and 
pregnancy complications in threatened miscarriage can be diminished by corpus luteum 
support by progesterone administration if the woman did not have a history of recurrent 
pregnancy loss.33 The women receiving an initial dose of 40 mg dydrogesterone, followed 
by 20 mg of dydrogesterone daily during one week had almost ten percentage point 
greater pregnancy success rate in comparison to the women who did not receive 
 16
dydrogesterone.33 The systematic analyses by Lee at al. supports these results, showing 
that progesterone therapy and dydrogesterone in particular is capable of significantly 
decrease the risk of pregnancy loss in the case of threatened miscarriage.31 Thereby 
progesterone indeed seems to be able to decrease the risk of later pregnancy 
complications in the case of threatened miscarriage. 
6.3 Habitual abortions 
When a woman miscarries three or more consecutive times with the same partner, she is 
said to have habitual abortions or recurrent miscarriage.82 It is estimated that incidence of 
habitual abortions is somewhere between 1-2%. Unfortunately, almost 50% of these cases 
are idiopathic even after comprehensive analyses and it is therefore complicated to find a 
successful treatment option. The majority of detectable explanations are found to be in 
luteal phase deficiency, aneuploidy with trisomies being the most frequent cause, 
derangement of immune responses as well as endocrinological abnormalities like diabetes 
and polycystic ovary syndrome (PCOS). In other words, a variety of factors like genetical, 
anatomical, or hormonal abnormalities, dietary deficiencies, endocrinological abnormalities 
as well as autoimmunity can be associated with habitual abortions.91 Endocrinological 
investigations of the thyroid, ovaries, as well as the pituitary should be performed. 
Reznikoff-Etievant et al. found an occurrence of autoantibodies in 33,9% of 678 otherwise 
healthy women with habitual abortions, with anticardiolipin being the most frequent 
autoantibody present.91 All women later received aspirin and/or prednisone. Women with a 
high concentration of aCL had a 27 percentage point lower success rate of live birth 
compared to the women with a negative autoantibody test.91 In habitual abortions, 
antiphospholipid antibody syndrome has been found positive in 10-20% where the most 
frequent antibodies were found to be aCL, LAC, and anti-beta2 glycoprotein I.92 
Since it is proven that progesterone is essential in pregnancy and that the removal of its 
main producer corpus luteum by luteectomy in early pregnancy frequently causes abortion 
before the 7th week of gestation, it is justifiable that progesterone has become the main 
treatment for women with habitual abortions.93,94 
The PROMISE trial published in 2016 was unable to show any evidence that progesterone 
supplementation in early pregnancy in women with unexplained habitual abortions would 
be beneficial for the pregnancy outcome.95 It is understandable that this is causing dispirit 
for the physicians as well as the patients eager to find a therapy to bring an end to a 
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couple’s recurrent pregnancy loss. Undeniably, all physicians caring for women with 
habitual abortions want to decrease this incidence by finding the right treatment. Sadly, 
progesterone has not been proven as beneficial as first anticipated in this patient group. To 
bring some positives to this, there are no detrimental effects on the mother or the fetus 
from progesterone therapy. This is crucial for ongoing trial like the PRISM (progesterone in 
threatened miscarriage) trial for other progesterone indications like fertility treatments 
(ISRCTN Number: 14163439). Also, nearly 70 percent of women with habitual abortions 
will become pregnant, regardless if they were prescribed progesterone or not. Other 
studies do however show beneficial effects of progesterone administration in women with 
habitual abortions.96,97 A cohort study showed that micronized progesterone starting during 
the luteal phase reduces the risk for habitual abortions.96 Evaluation of other trials 
including women with habitual abortions also concluded the efficacy of progesterone in 
reducing the risk of consecutive miscarriages when administered 17-OHPC IM injections 
weekly.97 This systematic review by Saccone et al. analyzed the effect of all types of 
progesterone administration in women with a history of unexplained habitual abortions. 
Women with habitual abortions benefit from synthetic progestogen administration like 
weekly intramuscular injections with 17-OHPC by showing a decreased incidence of 
habitual abortions in these circumstances.97 However, the review failed to show any 
benefit of natural progesterone administration.97 Study limitations made it challenging to 
adequately justify the dosage and route of its administration. Further trials are needed to 
further analyze the types of progesterone as well as dosing in order to properly 
recommend an optimal treatment regime. 
In the previously mentioned cohort study, Klinman and colleagues at Yale School of 
Medicine together with the University of Illinois have shown promising results in 
progesterone’s possible effect in reducing the risk of continuous pregnancy losses in 
women with habitual abortions if administered in the early weeks of pregnancy.96 They 
found an association between an anomalous endometrial function test and habitual 
abortions. The endometrial marker, nuclear cyclin E undergoes changes throughout the 
menstrual cycle and an abnormal expression has been shown to be associated with 
infertility due to deficient development of the endometrium. In other words, the pregnancy 
loss seems to be correlated with the inability of the woman’s uterine endometrium to 
preserve the embryo and therefore a pregnancy. During the greater part of the first 
trimester, the uteroplacental blood circulation is not adequately developed to support the 
pregnancy by itself. The endometrium is therefore needed to provide enough nutrients for 
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pregnancy maintenance during these initial eight weeks of pregnancy. By providing 
progesterone to these women, the risk of a lost pregnancy can be reduced by giving the 
endometrium a better chance to provide efficient nutrients for pregnancy maintenance. A 
17 percentage points higher pregnancy success rates were seen in women with habitual 
abortions when administered 100-200 mg of vaginal micronized progesterone twice daily, 
beginning three days after the LH surge.96 
6.4 Previous preterm delivery 
Multiple factors contribute to the risk of a preterm labor syndrome. Preterm labor syndrome 
is caused by a variety of pathological processes and is believed to be the cause of the 
majority of preterm births. The syndrome activates components of the common pathway of 
parturition just as a term labor does, however in the preterm labor syndrome, this 
activation is pathologic.98,99 Factors such as cervical insufficiency, stress, uterine 
overdistention, infection and/or inflammation, vascular disorders, uterine ischemia, 
breakdown of maternal-fetal tolerance, and hormonal disorders are some of the 
pathological processes associated with this syndrome.99 Intrauterine infections are 
estimated to cause 25-40 percent of all premature deliveries worldwide, most commonly 
due to bacterial chorioamnionitis - an inflammation of the fetal membranes. The earlier in 
pregnancy the preterm labor occurs, the greater the chance that there is an infectious 
etiology. There are several different bacteria associated with PTB. These include 
Mycoplasma hominis, Escherichia coli, Ureaplasma urealyticum, Klebsiella, Gardnerela 
vaginalis, Bacteroides, Peptostreptocossus, and group B streptococcus as well as 
Helicobacter pylori infections.100 Some extra-uterine infections such as malaria, can lead to 
the onset of inflammatory processes that activate the partition pathway via chemokine, 
cytokine and prostaglandin production.98 Placental thrombosis as a consequence of 
vascular disorders such as the increased generation of thrombin also contributes to an 
increased risk, as well as senescence of the decidua; failure of immune tolerance; a short 
cervix and cervical insufficiency; hormonal imbalance such as insufficient progesterone 
action; uterine overdistention or ischemia; and the effects of stress and anxiety during 
pregnancy.98,101,102 
The incidence of PTB is about 12 percent in the general population. In the situation of a 
previous PTB however, the risk increases to as much as 20 to 50 percent in consecutive 
pregnancies.103,104 The earlier the PTB occurred in preceding pregnancies, the greater the 
risk of a recurrent PTB. Additional contributing factors to a rise in frequency of PTB 
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includes a larger number of preceding preterm pregnancies which is almost twice as 
common in African American women.103 One of the main indications in trials evaluating the 
effect of progesterone therapy in women with recurrent PTB is hence the history of PTB in 
the past.23 
A transvaginal ultrasound is recommended in the week 18-20 of pregnancy if the woman 
had a previous spontaneous premature delivery before week 32 of pregnancy without 
further complications, alternatively a premature delivery before week 34 of pregnancy in 
combination with complications. As previously mentioned, FDA approved progesterone as 
a treatment for preterm delivery in 2011.11 In a case of a preceding singleton PTB and/or a 
sonographic short cervical length, progesterone supplementation has shown promising 
results in reducing the likelihood of a subsequent PTB.93 A 2013 meta-analysis evaluated 
36 trials from the Cochrane Pregnancy register and showed a symbolic decreased risk for 
PTB as well as perinatal mortality in women with a preceding spontaneous singleton PTB 
and/or a sonographic short cervical length.105 Results are unfortunately less bright in 
regards to multiple gestations where no effect of progesterone administration could be 
demonstrated.105 Due to the absence of data showing any efficacy of its administration, 
progesterone is not routinely used as a therapy in multiple gestations. In spite of this fact, 
17-OHPC is sometimes prescribed in the case of a history of PTB in the past. Since a 
preceding PTB of a singleton is a risk factor for an additional PTB in a multiple gestation 
and trials with 17-OHPC did not display any harm to the mother or fetus, it has been 
considered safe to prescribe in these circumstances.73,106 However, this can be 
questionable since available data on the efficacy is very limited.73 It is therefore justifiable 
not to prescribe progesterone in these circumstances.  
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7. CONCLUSION 
The pathophysiology of pregnancy is very complex, making research related to pregnancy 
complications such as habitual abortions, threatened miscarriages and preterm birth 
extremely challenging. Since the majority of women with a previous pregnancy 
complication such as spontaneous abortion or preterm delivery will not have the same 
issue in subsequent pregnancies, it is difficult to recognize the natural history of this 
condition and presume the effect of a treatment prescribed. Published data has given a lot 
of ambiguous results with the OPPTIMUM study being one of the largest studies most 
dubious to the effect of progesterone supplementation.18 The weakness of this study was a 
low compliance of 69%. Even though a newly published meta-analysis shows promising 
results with a 38% reduction of PTB with vaginal progesterone supplementation, there is 
still a lot of unanswered questions related to the efficacy of progesterone in pregnancy.11,17 
All of the data do have the same conclusion when it comes to multiple gestations 
regarding PTB prevention where all of the trials have failed to show efficacy of 
progesterone supplementation. Whether the ambiguity of previous published date in all 
other cases is due to poor study design or not is hard to tell. Furthermore, there is a wide 
variety of aetiology correlated to miscarriage and the heterogeneity of published trial data 
has not always been accounted for. However, there is no evidence that progesterone 
would put a mother or a child at any risk of harmful effects, giving a good reason why 
progesterone should still safely be administered until proven otherwise. Administration of 
progesterone to a pregnant woman at risk might not always show a statistical significant 
improvement in pregnancy outcome but can still bring some reassuring placebo effect to  a 
woman who might feel abandoned if not given any treatment options at all. Larger 
randomized controlled trials are needed to continue investigating effects of progesterone 
as prophylaxis or treatment in pregnancy and which factors help estimate the possible 
positive outcome of its use, as well as exploring other treatment options. 
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